Cumberland Pharmaceuticals Management
Management criteria checks 3/4
Cumberland Pharmaceuticals' CEO is A. Kazimi, appointed in Jan 1999, has a tenure of 26.33 years. total yearly compensation is $1.17M, comprised of 60.1% salary and 39.9% bonuses, including company stock and options. directly owns 38.09% of the company’s shares, worth $29.01M. The average tenure of the management team and the board of directors is 8.6 years and 12 years respectively.
Key information
A. Kazimi
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 60.14% |
| CEO tenure | 26.3yrs |
| CEO ownership | 38.1% |
| Management average tenure | 8.6yrs |
| Board average tenure | 12yrs |
Recent management updates
Recent updates
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%
May 13
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%
Mar 01Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Feb 21Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified
Jan 15Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 04Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Mar 07Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares
Jan 09Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S
Oct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Aug 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Mar 18Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 02Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Jul 20Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Apr 15Checking In On Cumberland Pharmaceuticals
Jan 04Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?
Nov 09We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation
Apr 21Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?
Feb 13One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts
Nov 19
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$3m |
| Dec 31 2024 | US$1m | US$702k | -US$6m |
| Sep 30 2024 | n/a | n/a | -US$11m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$1m | US$675k | -US$6m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$1m | US$635k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$7m |
| Dec 31 2021 | US$1m | US$610k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$590k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$1m | US$567k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$1m | US$545k | -US$11m |
Compensation vs Market: A.'s total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD645.80K).
Compensation vs Earnings: A.'s compensation has been consistent with company performance over the past year.
CEO
A. Kazimi (66 yo)
Mr. A. J. Kazimi, MBA, founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 26.3yrs | US$1.17m | 38.09% $ 29.0m | |
| VP & CFO | 4yrs | US$283.03k | 0.13% $ 102.2k | |
| VP of Trade & Distribution and Chief Compliance Officer | 8.6yrs | US$349.11k | 0.26% $ 194.7k | |
| Vice President of Sales & Marketing | no data | US$305.97k | 0.031% $ 23.8k | |
| Vice President of Organizational Development | no data | US$323.75k | 0.11% $ 83.1k | |
| Senior VP of Administrative Services & Corporate Secretary | no data | US$298.01k | no data | |
| Managing Director of Banking & Investor Relations | no data | no data | no data |
Experienced Management: CPIX's management team is seasoned and experienced (8.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 26.3yrs | US$1.17m | 38.09% $ 29.0m | |
| Member of Pharmaceutical Advisory Board | no data | no data | no data | |
| Independent Director | 6.7yrs | US$60.81k | 0.41% $ 314.8k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Chairman of Medical Advisory Board & Independent Director | 15.3yrs | US$74.00k | no data | |
| Member of Pharmaceutical Advisory Board | no data | US$233.65k | no data | |
| Director | 2.8yrs | US$50.31k | 0.057% $ 43.3k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Pharmaceutical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 8.7yrs | US$60.81k | 0.22% $ 165.3k | |
| Independent Director | 15.3yrs | US$59.81k | no data |
Experienced Board: CPIX's board of directors are seasoned and experienced ( 12 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 05:42 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cumberland Pharmaceuticals Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Irina Rivkind Koffler | Duncan-Williams, Inc. |
| David Windley | Jefferies LLC |